NASDAQ$VNDA
Vanda Pharmaceuticals Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Vanda reported a slight increase in total net product sales and advanced its clinical development pipeline.
Vanda Pharmaceuticals reported a 1% increase in total net product sales for Q3 2020 compared to Q3 2019, with $60.3 million in sales. The company's income before taxes was $8.4 million, and net income was $5.9 million. The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications were accepted by the FDA for priority review.
- Total net product sales were $60.3 million, a 1% increase compared to Q3 2019.
- HETLIOZ® net product sales increased by 5% to $39.6 million compared to Q3 2019.
- Fanapt® net product sales decreased by 6% to $20.7 million compared to Q3 2019.
- Income before taxes was $8.4 million, compared to $12.3 million in Q3 2019.
Headline financials
Revenue & EPS history
Vanda · Revenue · Quarterly
$60.3M
Revenue by segment
Vanda · $60.3M total across 2 segments · Q3 2020
- HETLIOZ$39.6M+5.4%65.7%
- Fanapt$20.7M-5.5%34.3%
Forward guidance
Vanda will continue to assess the impact of the evolving pandemic on its business and operations and will provide future updates to its financial guidance as necessary.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.7%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+24.8%
Q2 2019
Best reaction
-23.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.5% | -13.8% | -19.1% | |
| Q4 2025 | -17.6% | -16.6% | +18.6% | |
| Q3 2025 | -0.9% | -1.4% | +21.4% | |
| Q1 2025 | -3.9% | -9.1% | +5.3% | |
| Q4 2024 | -6.0% | -3.2% | +6.0% | |
| Q3 2024 | +4.8% | +11.5% | +1.0% | |
| Q2 2024 | -3.4% | -9.1% | -9.4% | |
| Q1 2024 | -8.6% | -7.8% | +11.7% | |
| Q4 2023 | +9.1% | +16.1% | +3.8% | |
| Q3 2023 | -23.7% | -23.0% | -15.1% | |
| Q2 2023 | -8.8% | -13.4% | -14.3% | |
| Q1 2023 | +7.0% | +7.9% | -5.6% | |
| Q4 2022 | -4.6% | -4.5% | -18.0% | |
| Q3 2022 | -4.8% | -0.2% | +2.5% | |
| Q2 2022 | -1.2% | +0.9% | -0.5% | |
| Q1 2022 | -6.2% | -0.1% | -0.8% | |
| Q4 2021 | -5.0% | -15.2% | -14.5% | |
| Q3 2021 | -11.8% | -11.9% | -21.2% | |
| Q2 2021 | -7.4% | -12.4% | -10.5% | |
| Q1 2021 | +5.1% | +7.2% | +8.6% | |
| Q4 2020 | +20.5% | +17.6% | +15.5% | |
| Q3 2020 | +3.8% | +3.5% | +17.2% | |
| Q2 2020 | +6.2% | +10.2% | -5.3% | |
| Q1 2020 | -4.4% | +0.4% | -2.5% | |
| Q4 2019 | -3.7% | -6.2% | -20.5% | |
| Q3 2019 | +7.6% | +10.2% | +29.4% | |
| Q2 2019 | +24.8% | +21.2% | +11.4% | |
| Q1 2019 | -3.1% | +1.3% | -9.9% | |
| Q4 2018 | +9.3% | +14.7% | -0.7% | |
| Q3 2018 | +16.7% | +12.5% | +37.2% | |
| Q2 2018 | +4.1% | +2.4% | -7.3% | |
| Q1 2018 | +10.6% | +11.0% | +25.1% | |
| Q4 2017 | +6.6% | +7.9% | +4.7% | |
| Q3 2017 | -16.8% | -16.5% | -11.7% | |
| Q2 2017 | +7.1% | +3.5% | +11.3% | |
| Q1 2017 | -0.3% | -3.3% | -8.0% | |
| Q4 2016 | -0.7% | +2.7% | -1.7% | |
| Q3 2016 | -8.4% | -2.3% | +4.7% | |
| Q2 2016 | +2.7% | +8.5% | +36.9% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -0.6% | — | — | |
| Q3 2015 | -9.5% | — | — | |
| Q2 2015 | +8.3% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | +8.3% | — | — | |
| Q2 2014 | -11.3% | — | — | |
| Q1 2014 | -20.2% | — | — | |
| Q4 2013 | +7.2% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +4.0% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -6.2% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +6.5% | — | — | |
| Q4 2009 | +6.5% | — | — | |
| Q3 2011 | -2.2% | — | — | |
| Q3 2010 | -2.2% | — | — | |
| Q4 2010 | -10.9% | — | — | |
| Q2 2011 | -10.9% | — | — | |
| Q2 2010 | -10.9% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q1 2010 | +7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro